The tweet was deleted by the author.
But we saved everything 🙂.
Immuneering employees gathered last weekend in Boston, New Jersey and San Diego to participate in the PanCAN PurpleStride event supporting pancreatic cancer awareness.
The company highlighted the enthusiasm, compassion, and teamwork displayed by its staff in multiple locations, reaffirming its ongoing commitment to improving outcomes and support for patients affected by pancreatic cancer.
The event follows Immuneering's recent work in cancer therapy, including the introduction of Deep Cyclic Inhibitors designed to reduce toxicity. The company has also shared updates on early-stage research in pancreatic cancer treatment, discussed by CEO Ben Zeskind on a recent BrewMarkets podcast episode. These initiatives form part of Immuneering’s broader focus on improving patient outcomes in oncology.